2. ABOUT US
Filterlex Medical Ltd is a medical device start-up in the
cardiovascular field. Filterlex develops a next generation
embolic protection device (EPD) for reducing the risk of
stroke and other complications during catheter-based left-
heart procedures.
2017
PARNASA 61 – Biomedical Fund
3. BERKSHIRE UNIVERSITY | COLLEGE OF ARCHITECTURE
GOAL
To develop the next generation
embolic protection device for
reducing the risk of stroke and other
complications during catheter-based
structural heart procedures.
PARNASA 61 – Biomedical Fund
2017
4. PRODUCT
The Filterlex embolic protection device
is constructed out of filter covered
collapsible frame and filter pockets. Its
unique structure is designed to provide
embolic protection to the brain and
other vital organs by deflecting embolic
particles from the aortic arch and
diverting them to the capturing pockets
of the device.
The particles remain in the pockets
and are extracted with the device. A
stable anchoring mechanism
prevents dislodgment of the device
and reduces potential interference to
the valve delivery system.
2017
PARNASA 61 – Biomedical Fund
5. 2017
ADVANTAGES
Provides full body embolic protection
Performs deflection, capture and removal of embolic
particles
Protects aorta surface
PARNASA 61 – Biomedical Fund
No interference to valve delivery system
6. MARKET
2017
The worldwide TAVI (Transcatheter
Aortic Valve Implantation) market is
estimated to surpass $3.02B by 2020
with a 19.7% Compound Annual
Growth Rate (CAGR). The global
TMVR (Transcatheter Mitral Valve
Repair) market opportunity is
estimated as 5 times the TAVI market.
An additional potential market is the
AF Ablation market, estimated at 1.2
million procedures annually. The total
addressable market for Filterlex is
valued at $2B annually.
MARKET LANDSCAPE
• First device in this field
received FDA clearance in
June 2017
• Claret Medical, Keystone
Heart (each raised over
$24M)
• Embrella (acquired by
Edwards Life sciences in
2011 for $43M).
PARNASA 61 – Biomedical Fund
7. HIGHLIGHTS
FOUNDATION
Founded in July 2015 located in Yokneam
FUNDS RAISED
Government funded incubator, Alon Medtech - $800K
Parnasa – $1000K
POTENTIAL MARKET
Addressable market by 2020 - $2 billion
2017
PARNASA 61 – Biomedical Fund
8. 2017
MIL ESTONES
Reached
Achieved proof of concept in animal model of device and
delivery + retrieval systems
PARNASA 61 – Biomedical Fund
Goals for 2017
Design freeze of device and delivery + retrieval systems
9. PARNASA 61 – Biomedical Fund
TEAM
2017
Sigal Eli – Inventor & CEO
• Interventional cardiology imaging expert with extensive experience in TAVI and
other catheter-based procedures, previously a clinical and training specialist at
Paieon Medical.
Ron Davidson – Active Board Member
• Over 18 years of experience in managing and accelerating companies in the
healthcare field. Led two companies from early stage to successful acquisitions by
multinational companies.
Eyal Teichman – CTO
• Entrepreneur, mechanical engineer and CTO with over 25 years of R&D experience
with extensive experience in implantable devices in the cardiovascular field.
10. PARNASA 61 – Biomedical Fund
TEAM
2017
Prof. Giora Weisz – Chairman of Advisory Board
• Until recently the Chairman of Cardiology at Sha’are Zedek Medical Center.
Associate Professor at Columbia University, NY and Hebrew University, Israel.
Renowned interventional cardiologist with extensive and established experience in
research and implementation of novel technologies in interventional cardiology.
Dr. Shimon Eckhouse – Chairman, Active Chairman at Alon MedTech Ventures
• One of Israel’s leading medical entrepreneurs and the owner of Alon MedTech
Ventures incubator. Founder and investor of numerous medical technology firms,
two of which are leading international companies, (ESC Medical [Lumenis] and
Syneron Medical), both traded on NASDAQ.
11. PARNASA 61- Biomedical Fund
An Israeli company managed by Parnasa Nihul Basad Ltd, seeking to raise $1.715 million in equity
capitalization.
The Company’s investment objective is to generate superior long-term capital appreciation through
private equity investments in early-stage private companies primarily based in the United States
and Israel.
The Investment Manager is controlled by Eliezer Gross who holds a controlling interest of
management shares of the Company. The Investment Manager will be responsible for the
Company’s investment strategy and the management of the Company. He will perform all day-to-
day investment and asset management functions for the Company, subject to the supervision and
direction of the Company’s Board of Directors.
The Company has been formed to make seed and early-stage investments in the common stock
and preferred stock of start-up technology ventures located in Israel.
2017
PARNASA 61 – Biomedical Fund
12. INVESTMENT STRATEGY
The Company intends to invest substantially all of the proceeds of the sale of Shares
offered in the existing portfolio.
In addition, the Company may invest (or reinvest proceeds of exited investments) in one
or more other start-up technology ventures from time to time subject to the availability of
resources.
The Company intends to have multiple closings so that any money that comes in could
immediately be used by the Company even if it is below the total amount of capital sought
to be raised pursuant to the official offering.
2017
PARNASA 61 – Biomedical Fund
13. FUND STRUCTURE
FUND LIFE
(TERM):
The Company’s existence is perpetual and therefore dissolution
and/or distribution of all or part of the Company’s assets are not
expected at any time in the future.
Minimum purchase of 6000 shares = $10,625.
Fund will bear all costs and expenses
FISCAL YEAR END:
CARRIED INTEREST:
December 31
25%
2017
OFFERING &
ORGANISATION
EXPENSES:
TAXATION: The Company is being treated as a corporation under the Israeli
tax laws.
PARNASA 61 – Biomedical Fund
MINIMUM
PURCHASE:
14. MANAGEMENT TEAM
With over 30 years of experience launching business ventures in
Israel, the United States, and Europe. He was a founding partner
of the American GBM Group, and of the largest retail chains in
Israel. Active in dozens of startup initiatives and companies
worldwide, he knows the U.S market inside and out and has been
influential in developing many new products. His keen business
acumen has led him through the doors of dozens of leading
companies – primarily from the Fortune 100 including: Johnson &
Johnson Corporation, CBS Studios, Goodyear Tires, et al.
Eliezer Gross,
Founder and Chairman
2017
PARNASA 61 – Biomedical Fund
15. MANAGEMENT TEAM
2017
Cobi Bitton,
CEO, Besadno Group
Mr. Bitton is an entrepreneur, organizational consultant, and expert in
business development and the study of entrepreneurial business models.
He holds a Bachelor's degree in Industrial and Management, a MBA and is
highly knowledgeable about conventional industrial production,
environmental issues, and safety and security products.
He was one of the entrepreneurs and founders of the SEC (Safe
Evacuation Coalition) - an advocacy group formed by companies, and
dedicated to promoting advanced emergency means of egress solutions in
the global market.
He has been counselling businesses, entrepreneurs, start-up's and
corporations for the past 25 years, empowering clients in the American,
Eastern and Central European, Latin, Russian, and East Asian markets,
among other locations. Cobi serves as the CEO of Israel - Greece
Chamber of Commerce, voluntarily.
PARNASA 61 – Biomedical Fund
16. MANAGEMENT TEAM
2017
Gabby Hasson,
CEO, Bseed Investments
Gabby is the CEO and Co-Founder of Bseed Investments, with over
25 years of proven experience in the Investment, IT and cutting-
edge technology space in navigating and uncovering opportunities
for excellent growth and profitability.
Previously, Gabby held management, Investment, and business
development positions, at CB Alliance (VC), IBM, and HP, as well as
Mashik Consulting and CTI. He specialized in uncovering and
enhancing solutions for Mobile Telecom, Banking, and Online
Marketing. Gabby gained vast experience with IBM's Global
Technology Unit (GTU), that focused on start-up's and innovations.
PARNASA 61 – Biomedical Fund
17. MANAGEMENT TEAM
2017
Oded Eliashiv
Head Of Development,
Besadno Group
Mr. Eliashiv (LLB) is the Head of Development in the Besadno
Group. Oded has vast experience in the Israeli start-up industry,
having led numerous ventures in leading companies including
Excellence Capital Group (Singapore), Excellence AgriTech
Solutions (Cambodia), Slyde, ElectroPep, Beyond Interactive and
Epos Technologies. Using his extensive experience in the start up
ecosystem, Oded is now advising early-stage start-up's and
providing them with the mentoring and fundraising assistance.
PARNASA 61 – Biomedical Fund
